June 2016
Together we can Cure Duchenne!
Research
oct2015_thumb04

Marathon Pharmaceuticals Announces Submission of Deflazacort New Drug Application to the FDA

Marathon Pharmaceuticals, LLC, a biopharmaceutical company developing treatments for rare diseases, on June 14 announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational drug deflazacort for the treatment of patients with Duchenne muscular dystrophy (DMD), the most common and most severe form of muscular dystrophy...

Read more.

oct2015_thumb04

Santhera's Marketing Authorization Application for RaxoneŽ in Duchenne Muscular Dystrophy (DMD) Validated by the European Medicines Agency

Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for RaxoneŽ for Duchenne muscular dystrophy (DMD) in patients with respiratory function decline who are not taking concomitant glucocorticoids...

Read more.

oct2015_thumb04

First Patient Enrolled in Summit’s PhaseOut DMD, A Phase 2 Clinical Trial of Ezutromid in Boys with DMD

Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, announced on June 17 that it has enrolled the first patient in PhaseOut DMD, a Phase 2 proof of concept clinical trial of ezutromid (formerly SMT C1100) in patients with DMD...

Read more.

oct2015_thumb04

Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy

A new paper in Neuromuscular Disorders on the Phase III trial of Raxone in Duchenne muscular dystrophy shows that patients on Raxone had significantly fewer pulmonary and airway infections, used fewer antibiotics and had fewer hospital visits than those in the study not on Raxone...

Read more.

oct2015_thumb04

CRISPR Therapeutics and Anagenesis Biotechnologies Announce Strategic In-Licensing and Collaboration Agreement to Develop CRISPR/Cas9-based Cell Therapies for Muscle Diseases

CRISPR Therapeutics and Anagenesis Biotechnologies announced on June 8 a strategic in-licensing and collaboration agreement, which grants CRISPR Therapeutics exclusive worldwide license to Anagenesis’ proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology for cell therapy for all human muscle diseases...

Read more.

oct2015_thumb04

BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa™ (drisapersen) in Europe

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced on May 31 that it has withdrawn its Kyndrisa™ (drisapersen) Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) following discussions at the May 2016 Committee for Medicinal Products for Human Use (CHMP) meeting...

Read more.

oct2015_thumb04

BioMarin Updates for the Duchenne Community

BioMarin has provided two updates for the Duchenne community in light of the recent announcement regarding their EMA marketing application...

Read more.

CureDuchenne Cares
jun2016_thumb17

Duchenne Families Meet and Learn in Long Island

Great day at the CureDuchenne Cares Conference! Very informative! It's been so great to connect with a such a great group of people!!! Thank you CureDuchenne for treating all of us to a very useful, hopeful and FREE workshop!” says Dustin, father of a boy with Duchenne...

Read more.

News
Vince Young Hosts Champions to CureDuchenne Event to Find a Cure for Duchenne Muscular Dystrophy

Webinar on Gene Therapy

CureDuchenne hosted a webinar with Bamboo Therapeutics on developing gene therapy for Duchenne muscular dystrophy on June 13...

Read more.

Vince Young Hosts Champions to CureDuchenne Event to Find a Cure for Duchenne Muscular Dystrophy

Getzlaf to Host 6th Annual Getzlaf Golf Shootout on August 26-27

Ducks captain Ryan Getzlaf and his wife Paige are hosting the 6th annual Getzlaf Golf Shootout to benefit CureDuchenne on August 26-27...

Read more.

Vince Young Hosts Champions to CureDuchenne Event to Find a Cure for Duchenne Muscular Dystrophy

Webinar on MoveDMD Clinical Trial of Edasalonexent

CureDuchenne and Catabasis Pharmaceuticals, Inc. hosted a webinar “MoveDMD: A Clinical Trial of Edasalonexent (CAT-1004) in Boys with Duchenne Muscular Dystrophy” on Wednesday, June 22, 2016...

Read more.

Upcoming Events
CureDuchenne Venture Philanthropy Model Featured in Forbes Insight Report

CureDuchenne Cares Workshop for Families, July 9, Chicago, IL

Please join CureDuchenne for a free, informative class on Duchenne muscular dystrophy on July 9 in Chicago, IL for family members and caregivers at Vitals Rehabilitation, 5820 W Irving Park Rd, Chicago from 9 a.m. 2 p.m...

Read more.

CureDuchenne Venture Philanthropy Model Featured in Forbes Insight Report

CureDuchenne Cares Workshop for Families, July 30, Sacramento, CA

Please join CureDuchenne for a free, informative class on muscular dystrophy on July 30 in Sacramento, CA for family members and caregivers at Shriner’s Hospital for Children, 2425 Stockton Blvd, Sacramento from 8:30 a.m. 2 p.m...

Read more.

CureDuchenne Venture Philanthropy Model Featured in Forbes Insight Report

CureDuchenne Cares Workshop for Families, August 13, Charlotte, NC

Please join CureDuchenne for a free, informative class on muscular dystrophy on August 13 in Charlotte, NC for family members and caregivers at Renaissance Charlotte South Park Hotel, 5501 Carnegie Blvd., Charlotte, NC 28209 from 8:30 a.m. to 2 p.m...

Read more.

CureDuchenne Venture Philanthropy Model Featured in Forbes Insight Report

Getzlaf Golf Shootout, August 26 and 27, Costa Mesa and Dana Point, CA

The 6th Annual Getzlaf Golf Shootout hosted by Ryan Getzlaf, captain of the Anaheim Ducks is a two-day charity golf event that brings together athletes, celebrities and community leaders, all teaming up in support of CureDuchenne...

Read more.

CureDuchenne Venture Philanthropy Model Featured in Forbes Insight Report

All in for Duchenne, October 15, Sylvania, OH

The annual All in for Duchenne event benefiting CureDuchenne is on October 15 from 6 p.m. to 11 pm. Tickets include admission to the event, dinner by Jeds Barbeque and Brew, drinks and chance to win in the reverse raffle. Proceeds of the event will help fund Duchenne muscular dystrophy research...

Read more.

CureDuchenne Venture Philanthropy Model Featured in Forbes Insight Report

Dealing for Duchenne, October 15, San Antonio, TX

Join us for a night of hope at the Dealing for Duchenne San Antonio on October 15...

Read more.

Powered By Convio